By Billy Candra 
New research from the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK) has provided a groundbreaking explanation for a long-standing paradox in colorectal cancer (CRC) immunology. While in most solid tumors, an abundance of regulatory T (Treg) cells is typically associated with worse patient outcomes due to their immune-suppressive function, colorectal cancer has historically presented a puzzling exception, often showing improved survival rates when these cells are present in higher numbers. The study, published in the scientific journal Immunity, reveals that Treg cells are not a monolithic entity but comprise distinct subtypes with opposing effects on tumor growth, a discovery that could revolutionize immunotherapy for the most common forms of CRC and potentially other cancers originating in barrier tissues.
The Enigma of Treg Cells in Cancer
Regulatory T cells are a specialized subset of T lymphocytes crucial for maintaining immune homeostasis and preventing autoimmunity. They act as "brakes" on the immune system, suppressing immune responses to self-antigens, harmless environmental factors, and beneficial microbes. However, in the context of cancer, their immunosuppressive role is often co-opted by tumors, allowing malignant cells to evade immune surveillance and destruction. This is why a high density of Treg cells within the tumor microenvironment is generally considered a negative prognostic indicator across a wide spectrum of cancers, including melanoma, lung cancer, and pancreatic cancer. The consistent observation of improved survival in colorectal cancer patients with higher Treg cell infiltration thus presented a significant challenge to this established paradigm, baffling researchers for years.
Dr. Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK, a world-renowned expert whose research over more than two decades has profoundly shaped the understanding of Treg cells, articulated the core finding: "Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it. It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches." This statement underscores the complexity of the immune system and the necessity for nuanced approaches in cancer therapy.
Decades of Foundational Research Culminate in a Breakthrough
The latest findings build upon a rich history of scientific inquiry led by Dr. Rudensky and his team. His pioneering work established the fundamental concept of "immune tolerance," elucidating how Treg cells prevent the immune system from attacking the body’s own tissues, commensal bacteria, and dietary antigens. Over the years, his lab has meticulously detailed the developmental pathways, functional mechanisms, and diverse influences of Treg cells on various physiological and pathological processes, including cancer development. This foundational knowledge was critical in designing the current study and interpreting its intricate results.
The multidisciplinary study was spearheaded by first authors Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, who also served as the study’s other senior author. Their combined expertise in immunology, medical oncology, and computational biology was instrumental in dissecting the complex immune landscape of colorectal cancer.
Focusing on the Predominant Form of Colorectal Cancer
Colorectal cancer remains a formidable public health challenge. According to the American Cancer Society, it ranks as the second leading cause of cancer-related death when statistics for men and women are combined. The disease is typically categorized by its molecular characteristics, which significantly influence prognosis and treatment response.
This MSK study specifically concentrated on the most prevalent form of the disease: microsatellite stable (MSS) colorectal cancer with proficient mismatch repair (MMRp). This subtype accounts for a substantial 80% to 85% of all CRC cases. Unfortunately, MSS CRC is notorious for its limited responsiveness to conventional checkpoint inhibitor immunotherapies, a class of drugs that have revolutionized treatment for other cancer types by unleashing the body’s immune system to attack tumors. For instance, earlier research, including work conducted at MSK, demonstrated remarkable efficacy of checkpoint inhibitors against the opposite tumor type – cancers with high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). Patients with MSI-H CRC can often achieve durable responses with immunotherapy alone, frequently allowing them to forgo aggressive treatments like surgery, chemotherapy, and radiation. The disparity in treatment outcomes between MSI-H and MSS CRC underscores the urgent need for novel therapeutic strategies for the latter, making the findings of the current study particularly impactful.
Unveiling the Dual Nature: Two Types of Treg Cells with Opposing Effects
To dissect the unique immunological environment of common colorectal cancers, the research team utilized a sophisticated mouse model meticulously developed at MSK. This model faithfully recapitulates the genetic alterations, pathological progression, and intricate immune milieu observed in human colorectal tumors, providing a highly relevant platform for mechanistic studies.
Their investigations led to a pivotal discovery: tumor-associated Treg cells within the CRC microenvironment are not uniform but can be classified into two principal groups based on their cytokine production profile. One group actively produces the signaling molecule interleukin-10 (IL-10), while the other does not.
Through a series of meticulously designed experiments involving the selective removal of each Treg cell group, the researchers elucidated their distinct and opposing influences on tumor progression:
-
IL-10-positive Treg cells: The Guardians Against Tumor Growth. These Treg cells were found to exert a protective effect, actively slowing tumor growth. Their mechanism involves reducing the activity of Th17 cells, another type of immune cell known to produce interleukin-17 (IL-17). IL-17 functions as a pro-inflammatory cytokine that, in the context of CRC, can act as a potent growth signal for tumor cells. Crucially, these beneficial IL-10-positive Treg cells were more frequently localized in the healthy tissue immediately adjacent to the tumor, suggesting a role in maintaining local immune balance. When these protective IL-10-positive Treg cells were experimentally depleted, tumors exhibited accelerated growth, confirming their tumor-restraining function.
-
IL-10-negative Treg cells: The Enablers of Tumor Progression. In stark contrast, the IL-10-negative Treg cells exhibited a detrimental effect. These cells were found to suppress the activity of potent immune defenders, particularly CD8+ T cells, which are widely recognized for their direct cancer-fighting capabilities and are critical mediators of anti-tumor immunity. This harmful subtype was predominantly situated within the tumor itself, suggesting a direct role in creating an immunosuppressive microenvironment that shields cancer cells. The targeted elimination of these IL-10-negative Treg cells resulted in significant tumor shrinkage, demonstrating their pro-tumorigenic role.
Clinical Validation: Patient Data Corroborates Experimental Findings
To bridge the gap between experimental models and human disease, the research team rigorously validated their findings using tumor samples obtained from actual colorectal cancer patients. Consistent with their observations in mouse models, they successfully identified two distinct populations of IL-10-positive and IL-10-negative Treg cells within these human samples.
Further strengthening the clinical relevance of their discovery, the team conducted a retrospective analysis of outcomes for over 100 colorectal cancer patients. The results were compelling: patients whose tumors harbored higher levels of the beneficial IL-10-positive Treg cells experienced significantly longer survival. Conversely, patients whose tumors contained a greater proportion of the harmful IL-10-negative Treg cells had demonstrably poorer outcomes.
Dr. Huang emphasized the clinical implications of these findings: "This research shows how important these positive cells are. And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." This sentiment underscores the potential for developing highly targeted immunotherapies that can fine-tune the immune response rather than broadly suppress or activate it.
A Promising Therapeutic Avenue: Targeting CCR8
The identification of distinct Treg cell subsets with opposing functions opens a promising new therapeutic avenue, particularly for MSS colorectal cancer patients who currently have limited immunotherapy options. The researchers discovered a critical distinguishing marker: IL-10-negative Treg cells, the harmful, immunosuppressive subtype predominantly found within tumors, express high levels of a protein called CCR8.
This finding aligns with earlier groundbreaking work from Dr. Rudensky’s lab, led by breast cancer surgeon George Plitas, MD. Their previous research had already established that CCR8 is highly expressed on tumor-infiltrating Treg cells in breast cancer and numerous other human malignancies. That work laid the foundation for the concept that antibodies specifically designed to deplete CCR8-expressing cells could selectively remove these harmful Treg cells from the tumor microenvironment. Such an approach would effectively disarm the tumor’s immune evasion strategy, allowing the patient’s own immune system to mount a more robust and effective attack against the cancer, all while leaving the beneficial, tissue-protective Treg cells intact.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky stated, highlighting the global impact and ongoing momentum of this research direction. Indeed, multiple clinical trials are currently underway at MSK and other leading institutions worldwide, investigating the efficacy of CCR8-targeting antibodies both as monotherapy and in combination with existing immunotherapies, such as checkpoint inhibitors. The current study significantly strengthens the rationale for deploying this precision immunotherapy strategy specifically in colorectal cancer and indicates its potential applicability across a broader spectrum of cancers.
Broader Implications: Similar Immune Patterns in Other Cancers
The researchers extended their investigation beyond colorectal cancer, analyzing a vast dataset of T cells derived from 16 different cancer types to ascertain whether similar immune patterns exist elsewhere. Their meticulous analysis revealed analogous divisions between IL-10-positive and IL-10-negative Treg cell populations in several other cancers affecting critical barrier tissues, including the skin and the linings of the mouth, throat, and stomach.
Dr. Mitra, who spearheaded the intricate data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky, offered a compelling explanation for this commonality: "What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses." This observation suggests a conserved immunological mechanism across barrier tissues, where a delicate balance of immune regulation is essential for maintaining health amidst constant external challenges. Consequently, the team postulates that therapeutic strategies designed to selectively remove IL-10-negative Treg cells in colorectal cancer could be equally effective against these other cancers that arise in similar barrier tissues, expanding the potential reach of this novel immunotherapy approach.
A Nuanced View: Different Immune Balance in Metastatic Disease
While the findings offer profound insights into primary colorectal tumors, the researchers also explored the immune landscape of metastatic disease, which often presents a distinct set of challenges. When they examined colorectal cancer that had metastasized to the liver, they observed a notably different immune pattern.
In these metastatic tumors, the balance shifted dramatically: the harmful IL-10-negative Treg cells significantly outnumbered the helpful IL-10-positive cells. Intriguingly, unlike in primary tumors where selective targeting is paramount, the removal of all Treg cells in this metastatic context led to the shrinkage of the tumors. This suggests that in advanced, metastatic settings, the overall immunosuppressive burden of Treg cells may outweigh the protective effects of the IL-10-positive subtype. This critical distinction highlights the imperative for treatment strategies that are not only tailored to the specific tissue of origin but also to the stage and progression of the disease, emphasizing the need for a highly personalized approach to cancer therapy.
Leadership, Funding, and Disclosures
This comprehensive study was supported by a robust collaborative effort. Additional contributing authors included Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh. Key infrastructural support was provided by the Integrated Genomics Operation and the Single Cell Research Initiative at MSK, underscoring the importance of advanced technological platforms in modern biomedical research.
The research received substantial financial backing from prestigious institutions and grants, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
As is standard practice in academic research with commercial implications, disclosures regarding potential conflicts of interest were made. Dr. Rudensky serves on scientific advisory boards and holds equity in several biotechnology and pharmaceutical companies, including Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member for Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and contributes as an editor to the Journal of Experimental Medicine and an editorial advisor to Immunity. Furthermore, Dr. Rudensky and Dr. Plitas are recognized as inventors on patents and patent applications held by MSK, specifically related to CCR8-based therapeutic depletion of tumoral Treg cells and the development of novel antibodies targeting CCR8. These disclosures ensure transparency and highlight the translational potential of the research.
The findings from the Sloan Kettering Institute represent a significant leap forward in understanding the complex interplay between the immune system and colorectal cancer. By resolving the long-standing paradox of Treg cells in CRC and identifying a specific therapeutic target in CCR8, this research offers renewed hope for millions of patients, particularly those with MSS colorectal cancer, who currently face limited treatment options. As clinical trials progress, the promise of precision immunotherapy, capable of selectively modulating the immune response, moves closer to becoming a reality, potentially transforming the landscape of cancer treatment.
